Christine M. Parseghian, M.D.
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2012 | Tufts University School of Medicine, Boston, MA, USA, MD, Doctor of Medicine with Research Honors |
| 2007 | Harvard University, Cambridge, MA, USA, BA, Neurobiology |
Postgraduate Training
| 2015-2018 | Clinical Fellowship, Hematology/Oncology Fellow, U.T. MD Anderson Cancer Center, Houston, TX |
| 2012-2015 | Clinical Residency, Internal Medicine Residency, Ronald Reagan University of California, Los Angeles, CA |
Board Certifications
| 2018 | American Board of Medical Oncology |
| 2016 | American Board of Internal Medicine |
Experience & Service
Administrative Appointments/Responsibilities
Biostatistics Chair Search Committee Member, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present
Faculty Senate, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Other Appointments/Responsibilities
Member, Cancer Center Support Grant Program (CCSG), Houston, TX, 2022 - Present
Institutional Committee Activities
Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer University of Texas MD Anderson Cancer Center, Houston, TX, Committee Member of Medical Staff, 2022 - Present
Committee Member, Junior Faculty Advisory Committee, 2018 - Present
Fellow, Dolores Zohrab Liebmann Fellow in Graduate Studies, 2008 - 2012
Community Service, Leopold Schepp Foundation Scholar for commitment to community service, 2008 - 2009
Fellow, David F. Noonan Tufts Summer Research, 2008 - 2009
Clinical Assistant, USAID and Armenian Medical Association, 2005 - 2006
Honors & Awards
| 2022 | Patient Experience Top 10% Recognition Provider |
| 2020 | Andrew Sabin Family Foundation |
| 2019 | Gastrointestinal SPORE Career Enhancement Program Award 2019-2021 |
| 2019 | NIH/NCI Gastrointestinal SPORE Career Enhancement Program Award, NIH/NCI |
| 2018 | 2018 Conquer Cancer Foundation of ASCO Merit Award |
| 2013 | Commendation for Excellence in Medical Student Teaching |
| 2012 | Solomon Research Scholar |
| 2012 | Tufts University School of Medicine Research Honors |
| 2012 | William Dameshek Award for Research Excellence in Hematology |
| 2012 | William Dameshek Award in Internal Medicine |
| 2007 | Harvard Foundation Distinguished Senior Award for Excellence in Leadership and Academic Achievement |
| 2005 | Harvard Foundation Award for Contributions to Intercultural and Race Relations |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Simmons K, Thomas JV, Ludford K, Willis JA, Higbie VS, Raghav KPS, Johnson B, Dasari A, Kee BK, Parseghian CM, Lee MS, Le PH, Morelli MP, Shen JP, Bent A, Vilar E, Wolff RA, Kopetz S, Overman MJ, Morris VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun 3(12):2510-2517, 2023. PMID: 38085001.
- Napolitano S, Parikh AR, Henry J, Parseghian CM, Willis J, Raghav KP, Morris VK, Johnson B, Kee BK, Dasari AN, Overman MJ, Luthra R, Drusbosky LM, Corcoran RB, Kopetz S, Sun R. Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing. JCO Precis Oncol 7:e2300228, 2023. PMID: 37824798.
- Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, Huey RW, Johnson B, Kee B, Lee MS, Morelli MP, Morris VK, Overman MJ, Parseghian C, Raghav K, Willis J, Wolff RA, Kawaguchi Y, Vauthey JN, Sun R, Kopetz S, Shen JP. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol 7(1):16, 2023. e-Pub 2023. PMID: 36781990.
- Parseghian CM, Sun R, Woods M, Napolitano S, Lee HM, Alshenaifi J, Willis J, Nunez S, Raghav KP, Morris VK, Shen JP, Eluri M, Sorokin A, Kanikarla P, Vilar E, Rehn M, Ang A, Troiani T, Kopetz S. Resistance Mechanisms to Anti-EGFR Therapy in RAS/RAF Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy. J Clin Oncol:101200JCO2201423. e-Pub 2022. PMID: 36351210.
- Davis JS, Chavez JC, Kok M, San Miguel Y, Lee HY, Henderson H, Overman MJ, Morris V, Kee B, Fogelman D, Advani SM, Johnson B, Parseghian C, Shen JP, Dasari A, Shaw KR, Vilar E, Raghav KP, Shureiqi I, Wolff RA, Meric-Bernstam F, Maru D, Menter DG, Kopetz S, Chang S. Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. JAMA Netw Open 5(10):e2236357, 2022. e-Pub 2022. PMID: 36239938.
- Morris VK, Overman MJ, Lam M, Parseghian CM, Johnson B, Dasari A, Raghav K, Kee BK, Huey R, Wolff RA, Shen JP, Li J, Zorrilla I, Tzeng CD, Tran Cao HS, Chun YS, Newhook TE, Vauthey N, Duose D, Luthra R, Haymaker C, Kopetz S. Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res Commun 2(9):979-986, 2022. e-Pub 2022. PMID: 36382087.
- Serpas Higbie V, Rogers J, Hwang H, Qiao W, Xiao L, Dasari A, Mola-Rudd K, Morris VK, Wolff RA, Raghav K, Huey R, Parseghian C, Willis J, Kopetz S, Overman MJ, Johnson B. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience. Oncologist. e-Pub 2022. PMID: 35946836.
- Ibraheim MK, Lo J, Gupta R, Parseghian C, Patel AB. Acneiform eruptions with combination targeted cancer therapy in colorectal cancer patients. Support Care Cancer. e-Pub 2022. PMID: 35771289.
- Newhook TE, Overman MJ, Chun YS, Dasari A, Tzeng CD, Cao HST, Raymond V, Parseghian C, Johnson B, Nishioka Y, Kawaguchi Y, Uppal A, Vreeland TJ, Jaimovich A, Arvide EM, Cristo JV, Wei SH, Raghav KP, Morris VK, Lee JE, Kopetz S, Vauthey JN. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Ann Surg. e-Pub 2022. PMID: 35797554.
- Shen C, Tannenbaum D, Horn R, Rogers J, Eng C, Zhou S, Johnson B, Kopetz S, Morris V, Overman M, Parseghian C, Chang GJ, Lopez-Olivo MA, Kanwal R, Ellis LM, Dasari A. Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review. JAMA Netw Open 5(5):e2213588, 2022. e-Pub 2022. PMID: 35608860.
- Morris V, Kee B, Overman M, Dasari A, Raghav K, Johnson B, Parseghian C, Wolff RA, Garg N, Eng C, Kopetz S. Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. J Gastrointest Oncol 13(2):647-656, 2022. PMID: 35557581.
- Kanikarla Marie P, Haymaker C, Parra ER, Kim YU, Lazcano R, Gite S, Lorenzini D, Wistuba II, Tidwell RSS, Song X, Foo WC, Maru DM, Chun YS, Futreal A, Kee B, Menter D, Solis L, Tzeng CW, Parseghian C, Raghav K, Morris V, Chang CC, Jenq R, Tam A, Bernatchez C, Kopetz S, Vauthey JN, Overman MJ. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res 27(11):3039-3049, 2021. e-Pub 2021. PMID: 33811152.
- Henry JT, Coker O, Chowdhury S, Shen JP, Morris VK, Dasari A, Raghav K, Nusrat M, Kee B, Parseghian CM, Pant S, Jeyakumar N, Zhu L, Nishioka Y, Fogelman D, Wolff RA, Hong D, Overman MJ, Vauthey J, Kopetz S, Johnson B. Comprehensive Clinical and Molecular Characterization of KRAS G12C-Mutant Colorectal Cancer. JCO Precision Oncology, 2021. PMID: 34250391.
- Cherng HJ, Jain N, Thakral B, Muzzafar T, Miranda RN, Tan D, Rashid A, Kalhor N, Hahn AW, Byers LA, Parseghian CM, Ferrajoli A, Pemmaraju N. Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia. Leuk Res 98:106445, 2020. e-Pub 2020. PMID: 32937250.
- Favazza LA, Parseghian CM, Kaya C, Nikiforova MN, Roy S, Wald AI, Landau MS, Proksell SS, Dueker JM, Johnston ER, Brand RE, Bahary N, Gorantla VC, Rhee JC, Pingpank JF, Choudry HA, Lee K, Paniccia A, Ongchin MC, Zureikat AH, Bartlett DL, Singhi AD. KRAS amplification in metastatic colon cancer is associated with a history of inflammatory bowel disease and may confer resistance to anti-EGFR therapy. Mod Pathol 33(9):1832-1843, 2020. e-Pub 2020. PMID: 32376853.
- Gay CM, Parseghian CM , Byers LA. This Is Our Cells Under Pressure: Decreased DNA Damage Repair in Response to Targeted Therapies Facilitates the Emergence of Drug-Resistant Clones. Cancer Cell 37(1):5-7, 2020. PMID: 31951562.
- Clifton K, Rish TA, Parseghian CM, Raymond VM Dasari A, Pereira AA, Willis J, Loree JM, Bauer TM, Chae YK, Sherill G, Fanta P, Grothey A Hendifar A, Henry D, Mahadevan D, Nezami MA, Tan B, Wainberg ZA, Lanman R, Kopetz S Morris V. Identification of ACtionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. JCO Precision Oncology, 2019.
- Johnson B, Loree JM, Jacome AA, Mendis S, Syed M, Morris VK Parseghian CM , Dasari A, Pant S, Raymond VM, Vilar E, Overman M, Kee B, Eng C, Raghav K, Kopetz S. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO Precision Oncology, 2019. e-Pub 2019.
- Parseghian CM , Napolitano S, Loree JM, Kopetz S. Mechanisms of Innate and Acquired Resistance to anti-EGFR therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. Clin Cancer Res, 2019. e-Pub 2019. PMID: 31263029.
- Parseghian CM, Tam AL, Yao J, Ensor J, Ellis LM, Raghav K, Overman MJ. Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology. JAMA Oncol 5(3):402-405, 2019. e-Pub 2018. PMID: 30383128.
- Parseghian CM , Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S. Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge. Ann Oncol 30(2):243-249, 2019. PMID: 30462160.
- Parseghian CM , Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother 41(6):284-291, 2018. PMID: 29668571.
- Parseghian CM , Raghav K, Wolff RA, Ensor J, Yao J, Ellis LM, Tam AL, Overman MJ. Underreporting of Research Biopsies from Clinical Trials in Oncology. Clin Cancer Res 23(21):6450-6457, 2017. e-Pub 2017. PMID: 28754815.
- Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res 23(15):4146-4154, 2017. e-Pub 2017. PMID: 28280091.
- Thierry AR, Pastor B, Jiang ZQ, Katsiampoura AD, Parseghian CM , Loree JM, Overman MJ, Sanchez C, Messaoudi SE, Ychou M, Kopetz S. Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer. Clin Cancer Res 23(16):4578-4591, 2017. e-Pub 2017. PMID: 28400427.
- Megerdichian C, Olimpiadi Y, Hurvitz SA. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer. Cancer Treat Rev 40(5):614-25, 2014. e-Pub 2014. PMID: 24560997.
- Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian CM, Wilson FH, Currie T, Khanna-Gupta A, Berliner N, Kutok JL, Ebert BL. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood 117(9):2567-76, 2011. e-Pub 2010. PMID: 21068437.
- Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, Paktinat M, Haydu JE, Housman E, Lord AM, Wernig G, Kharas MG, Mercher T, Kutok JL, Gilliland DG, Ebert BL. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 17(6):584-96, 2010. PMID: 20541703.
- Megerdichian CL, Rees VW, Wayne GF, Connolly GN. Internal tobacco industry research on olfactory and trigeminal nerve response to nicotine and other smoke components. Nicotine Tob Res 9(11):1119-29, 2007. PMID: 17978985.
Invited Articles
- Eluri M, Kopetz S, Parseghian CM. Truncal dynamics may trump: serial ctDNA to predict early therapeutic response. Clin Cancer Res. e-Pub 2022. PMID: 36378102.
Abstracts
- Parseghian CM, Lee JK, Quintanilha J, Schrock AB, Graf R, Pasquina L, Sivakumar S, Oxnard G, Tukachinsky H, Klempner SJ, Kopetz S.. Potential Mechanisms of Acquired Resistance to Anti-EGFR Monoclonal Antibody (mAb) Therapy Detected in Liquid Biopsies from Patients with Advanced Colorectal Cancer. J Clin Oncol 42, 2024.
- Parseghian CM, Vilar Sanchez E, Sun R, Eluri M, Morris VK, Johnson B, Morelli MP, Overman MJ, Willis J, Huey R, Raghav KP, Dasari A, Kee BK, Wolff RA, Shen JP, Kopetz S. Phase 2 Study of Anti-EGFR Rechallenge Therapy with Panitumumab with or without Trametinib in Advanced Colorectal Cancer. ASCO Annual Meeting, 6/2022 40(16), 2022.
- Parseghian CM, Ryan Sun, Melanie Nicole Woods, Stefania Napolitano, Jumanah Alshenaifi, Jason Willis, ShaKayla Kentel Nunez, Alexey Sorokin, Preeti Kanikarla Marie, Kanwal Pratap Singh Raghav, Van K. Morris, John Paul Y.C. Shen, Eduardo Vilar Sanchez, Marko Rehn, Agnes Ang, Teresa Troiani, Scott Kopetz. Resistant Mechanisms to anti-EGFR Therapy in RAS/RAF Wildtype Colorectal Cancer Varies by Regimen and Line of Therapy. ASCO Annual Meeting, 6/2022 40(16), 2022.
- Parseghian CM, Ryan Sun, Stefania Napolitano, Van K. Morris, Jason Henry, Jason Willis, Eduardo Vilar Sanchez, Kanwal Pratap Singh Raghav, Agnes Ang, Scott Kopetz. Rarity of acquired mutations (MTs) after first-line therapy with anti-EGFR therapy (EGFRi). Journal of Clinical Oncology ASCO Annual Meeting 2021 39(15), 2021.
- Parseghian CM, Willis J, Morris V, Raghav K, Dasari A, Raymond V, Lanman R, Overman MJ, Kopetz S. Identifying anti-EGFR (EGFRi) response subgroups using evidence of ctDNA selective pressure. ASCO Annual Meeting, 2019.
- Rich TA, Clifton K,Raymond VM, Dasari A, Raghav K, Parseghian CM , Lanman RB, Kopetz S, Morris VK. Association between gene fusions and anti-EGFR resistance signature in colorectal cancer. J Clin Oncol(3564), 2019.
- Horn RA, Tannenbaum D, Morris VK, Johnson B, Overman MJ, Parseghian CM, Scott Kopetz, Eng C, Rogers JE, Raghav K, Dasari A,. Reporting of patient characteristics and use of stratification factors in phase III trials for metastatic colorectal cancer: Urgent need for standardization. J Clin Oncol 37(suppl), 2019.
Book Chapters
- Parseghian, CM. Colorectal Liver Metastases. In: Targeted Therapy Beyond EGFR and VEGF, 2022.
- Parseghian CM. Colorectal Cancer. In: The MD Anderson Manual of Medical Oncology. Fourth Edition, 2021.
Grant & Contract Support
| Title: | Open-label Phase Ib/II Study of Cetuximab Administered in Combination with LY3214996 (ERK 1/2 Inhibitor) or Cetuximab in Combination with LY3214996 and Abemaciclib in Patients with Metastatic, Anti-EGFR-Refractory Colorectal Cancer |
| Funding Source: | Eli Lilly and Company |
| Role: | Principal Investigator |
| Title: | Phase II Enrichment Study of Panitumumab as a Single Agent or in Combination with Trametinib in anti-EGFR Refractory Stage IV Colorectal Cancer Patients |
| Funding Source: | Amgen Inc |
| Role: | Principal Investigator |
| Title: | Optimizing Anti-Rechallenge Therapy in Advance Colorectal Cancer |
| Funding Source: | Andrew Sabin Family Foundation Fellowship |
| Role: | Principal Investigator |
| Title: | A Phase II Enrichment Study of Panitumumab as a Single Agent or in Combination With Trametinib in Anti_EGFR-Refractory Stage IV Colorectal Cancer Patients |
| Funding Source: | Novartis |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified November 04, 2024